| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Finch Therapeutics Group Inc. | CP101 - (PRISM-EXT) | C. difficile Infection | Phase 2 | Trial Discontinued | Oral | Antibiotic |
| Finch Therapeutics Group Inc. | CP101 - (PRISM3) | Clostridioides difficile infection | Phase 2 | Oral | Gastroenterology | |
| Forte Biosciences Inc. | FB102 | Celiac Disease | Phase 2 | Ongoing | Intravenous | Gastroenterology |
| Forte Biosciences Inc. | FB-401 | Atopic Dermatitis | Phase 2 | Trial Discontinued | Topical | Immunology |
| Fortress Biotech Inc. | CEVA101 | Severe Traumatic Brain Injury | Phase 2 | Trial Discontinued | intravenous | Neurology |
| Fortress Biotech Inc. | CMV-MVA Triplex Vaccination | Hematopoietic stem cell transplantation (HSCT) | Phase 2 | Enrollment Initiation | Intramuscular | Hematology |
| Fortress Biotech Inc. | Dotinurad - (TOPAZ) | Tophaceous gout | Phase 3 | Ongoing | Oral | N/A |
| Fortress Biotech Inc. | MB-107 | X-linked Severe Combined Immunodeficiency (XSCID) - newly diagnosed infants | Phase 2 | Data Released | Intravenous | Genetic Disorder |